Results: Out of the 160 COVID-19 patients, 32 were moderately ill (males: 29, females: 03)
and were treated with remdesivir along with steroids and low molecular weight heparin …

Background Real-world data on safety and clinical outcomes of remdesivir in COVID-19
management is scant. We present findings of data analysis conducted for assessing the …

The expanding epidemic of coronavirus disease 2019 (COVID-19), caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a serious threat to the …

Background Remdesivir is a US Food and Drug Administration-approved drug for
coronavirus disease 2019 (COVID-19). Clinical trials were conducted under strictly …

For the treatment of Covid‐19 patients with remdesivir, poor renal and liver function were
both exclusion criteria in randomized clinical trials and contraindication for treatment. Also …

In 2002, severe acute respiratory syndrome (SARS) first appeared in China. It quickly spread
worldwide within 3 months, resulting in the first pandemic of the twenty‐first century with a …

Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

Context Following the emergence of the novel severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) …

Methods: Participants more than 40-years old and with moderate to severe COVID-19 but
not on mechanical ventilation were randomly assigned into two groups-remdesivir group (34 …

Objective: To determine the effect of Remdesivir on liver enzymes and renal functions in
SARS-CoV-2 patients. Methods: This prospective cohort study was conducted at Dr. Ruth …